{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:11:06Z","timestamp":1792602666706,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtho.2024.11.032","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:37:48Z","timestamp":1732952268000},"page":"487-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC"],"prefix":"10.1016","volume":"20","author":[{"given":"Kazuhiko","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Ponce","family":"Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie Y.K.","family":"Chik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunoj","family":"Chacko Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Frimodt-Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.11.032_bib1","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.3390\/ijms24108878","article-title":"Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need","volume":"24","author":"Pretelli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2024.11.032_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-Mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib6","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.21037\/tcr-23-956","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.032_bib7","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3816\/CLC.2007.s.006","article-title":"Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer","volume":"8","author":"Byers","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.11.032_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","article-title":"Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the Beverly multicenter randomized phase 3 trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.11.032_bib12","article-title":"Overcoming resistance to osimertinib by T790M loss and C797S acquisition using gefitinib in a patient with EGFR-mutant NSCLC: a case report","volume":"4","author":"Enrico","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2024.11.032_bib13","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.3390\/cancers13143600","article-title":"Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening","volume":"13","author":"Adashek","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.11.032_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.032_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib17","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2020.38.15_suppl.9506","article-title":"NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations","volume":"38","author":"Maemondo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv133","article-title":"Detecting overall survival benefit derived from survival postprogression rather than progression-free survival","volume":"107","author":"Morita","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2024.11.032_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.11.032_bib20","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2217\/fon-2020-0203","article-title":"Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation","volume":"16","author":"Imamura","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib21","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.23.01521","article-title":"Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non-small-cell lung cancer","volume":"42","author":"Remon","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib22","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-21-0273","article-title":"RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer","volume":"27","author":"Nakagawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.032_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","article-title":"RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome","volume":"24","author":"Nishio","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2020.04.004","article-title":"Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors","volume":"145","author":"Cheng","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-023-10637-4","article-title":"Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE Study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib27","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","article-title":"Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L)","volume":"23","author":"Haratake","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.11.032_bib29","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.032_bib30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA: phase 3 study of first-line amivantamab\u00a0+ lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy","volume":"75","author":"Schwaederl\u00e9","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.032_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","article-title":"Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome","volume":"85","author":"Teodoro","year":"2007","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jtho.2024.11.032_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18632\/oncotarget.974","article-title":"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy","volume":"4","author":"Said","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.11.032_bib34","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.11.032_bib35","volume":"42","author":"Yang","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40264-021-01127-2","article-title":"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor mutation-positive, metastatic non-small-cell lung cancer: safety profile and manageability","volume":"45","author":"Nadal","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtho.2024.11.032_bib37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/03007995.2020.1808781","article-title":"Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer","volume":"36","author":"Yoh","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtho.2024.11.032_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad013","article-title":"Ramucirumab plus docetaxel for patients with non-small cell lung cancer with brain metastases: a multicenter, open-label single-arm phase II trial","volume":"28","author":"Tanimura","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.11.032_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/COC.0b013e3182438c91","article-title":"The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients","volume":"36","author":"Bai","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.11.032_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102583","article-title":"4O First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2024.11.032_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na\u00efve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642402495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642402495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:00:01Z","timestamp":1748970001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608642402495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S155608642402495X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.11.032","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}